SCHEMBL3451572

SCHEMBL3451572

CCN(CC)S(=O)(=O)c1cncc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PIK3CD O00329 1/20 0.39
PIK3CG P48736 1/20 0.39
LMNA P02545 5/20 0.38
MAPT P10636 3/20 0.38
KDM4E B2RXH2 3/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
HTT P42858 2/20 0.37
TSHR P16473 1/20 0.37
HPGD P15428 2/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
NAMPT P43490 1/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3627382 0.85 CA1 (0.36) ALDH1A1NPC1RAB9ACA1CA2
SCHEMBL3264039 0.80 CA1 (0.39) PIK3CDPIK3CGCA1CA2CA9
SCHEMBL15550950 0.80 ALDH1A1 (0.55) ALDH1A1LMNAMAPTKDM4EMEN1
SCHEMBL12505280 0.79 NAPRT (0.39) CA1CA2CA9LPLLIPG
SCHEMBL471553 0.79 LMNA (0.54) LMNAMEN1KMT2ASMN1; SMN2HTT
SCHEMBL3117072 0.79 CA1 (0.46) CA1CA2CA9LPLLIPG
SCHEMBL3449870 0.78 LPL (0.37) ALDH1A1SMN1; SMN2NAMPTCA1CA2
SCHEMBL14247351 0.76 CA1 (0.39) PIK3CDPIK3CGMAPTCA1CA2
SCHEMBL19820792 0.75 CA1 (0.41) CA1CA2CA9LPLLIPG
SCHEMBL1502812 0.74 ALDH1A1 (0.39) ALDH1A1NPC1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012174312-A2 BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2012-12-20 WO disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD ALDH1A1 530/4885NPSR1 2715/4885PIK3CD 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.